SHENZHEN, GUANGDONG, CHINA, January 8, 2026 /EINPresswire.com/ -- As a Top Rated Li-Ion Battery Fabrication Supplier, ...

SHENZHEN, GUANGDONG, CHINA, January 7, 2026 /EINPresswire.com/ -- Performance and safety of advanced energy storage ...

BRISTOL, Tenn. (WJHL) — The MLB Speedway Classic will break the league’s record for regular-season single-game attendance, Bristol Motor Speedway (BMS) announced on Monday. In a news release, BMS ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year. Still, even as ...

Look at just about any discussion of an electric vehicle’s (EV) battery lifetime and there’s alleged handwringing over statutory warranty periods, cost of replacement, and industry capacity to recycle ...

Automotive BMS must undergo rigorous testing to verify that it meets stringent performance and safety standards. BMS emulation involves using hardware and software tools to simulate the behavior of a ...

BMS Group, the independent specialist insurance and reinsurance broker with an operation in Bermuda, has agreed to acquire David Roberts & Partners, the British-based independent insurance broker.

Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program. Agenus ...

Bristol Myers Squibb has had a whiplash change of heart on its BCMA bispecific T-cell engager, halting (PDF) further development months after filing to run a phase 3 trial. The Big Pharma disclosed ...